Objective: To investigate the application of metabonomics in research of osteoporosis, through detecting change of the endogenous metabolites in plasma from osteoporotic rats by ovariectomy.
Methods: Six old-months female SD rats were randomly divided into sham and OVX group. Fifth month after ovariectomy, plasma were collected from both groups, respectively. The metabolic profiles were investigated using 1H-NMR spectroscopy of plsama combined with pattern recognition techniques, including principal component analysis (PCA) and partial least squares-discriminant analysis (PLS-DA).
Results: The PCA PLS-DA plots of the plasma samples presented marked clustering between sham group and OVX group. Compared to sham group, the level of low molecular metabolites such as lactate, acetone and ethonal were higer, glucose, choline/phosphatidylcholine (Cho/PC), alanine (Ala), high density lipoprotein/low density lipoprotein (HDL/LDL), very low density lipoprotein/low density lipoprotein, fatty acid and glucose were lower.
Conclusion: Obvious changes in metabonomics of plasma from osteoporotic rats were observed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Synthesis and Structure-Activity Relationships of Novel Benzofuran Derivatives with Osteoblast Differentiation-Promoting Activity.
Chem Pharm Bull (Tokyo)
January 2025
Drug Discovery Research Department, Kyoto Pharmaceutical Industries, Ltd.
Osteoporosis is caused by an imbalance between bone resorption and formation, which decreases bone mass and strength and increases the risk of fracture. Therefore, osteoporosis is treated with oral resorption inhibitors, such as bisphosphonates, and parenteral osteogenic drugs, including parathyroid hormone and antisclerostin antibodies. However, orally active osteogenic drugs have not yet been developed.
View Article and Find Full Text PDFA Novel Series of Coumarin Derivatives That Exert Osteoblastogenic Effects in Mesenchymal Stem Cells and Osteogenic Effects in Ovariectomized Female Rats.
Chem Pharm Bull (Tokyo)
December 2024
Drug Discovery Research Department, Kyoto Pharmaceutical Industries, Ltd.
Osteoporosis is treated with oral and parenteral resorption inhibitors and parenteral osteogenic drugs. However, orally active small-molecule osteogenic drugs are not clinically available. Natural coumarin derivatives, such as osthole, exert osteoblastogenic effects.
View Article and Find Full Text PDFiPSCs-derived iMSCs prevent osteoporotic bone loss and affect bone metabolites in ovariectomized mice.
J Cell Mol Med
November 2024
Yunnan Provincial Key Laboratory of Public Health and Biosafety and School of Public Health, Kunming Medical University, Kunming, Yunnan, China.
Osteoporosis is a metabolic bone disease that seriously jeopardizes the health of middle-aged and elderly people. Mesenchymal stem cell-based transplantation for osteoporosis is a promising new therapeutic strategy. Induced mesenchymal stem cells (iMSCs) are a new option for stem cell transplantation therapy.
View Article and Find Full Text PDFEvaluation of resveratrol's protective effect on hydrocortisone-induced growth inhibition in the peripubertal rat epiphyseal plate.
Tissue Cell
December 2024
Ankara University, Faculty of Medicine, Department of Medical Pharmacology, Ankara, Turkey. Electronic address:
Objective: Chronic use of glucocorticoids during childhood can lead to a decrease in hormone release, including ACTH, GH, TSH, and LH, as well as reduced IGF-1 activity. This can result in osteoporotic changes and hinder growth in height. Resveratrol, an antioxidant with phytoestrogen properties, may improve bone health by increasing bone mineral density in postmenopausal women.
View Article and Find Full Text PDFPossible role of bone turnover markers in the diagnosis of adult hypophosphatasia.
J Bone Miner Res
December 2024
Clinica Medica 1, Department of Medicine, University of Padua, European Reference Network on Rare Bone Diseases (ERN BOND), 35128 Padova, Italy.
Hypophosphatasia (HPP) is a rare disorder of the bone metabolism, characterized by genetically determined low alkaline phosphatase (ALP) activity. Low ALP may also be observed in some common causes of bone fragility, such as in osteoporosis treated with antiresorptive drugs. This study aimed to verify whether differences in bone turnover markers (BTMs) could help differentiate adult patients with HPP from those with osteoporosis undergoing antiresorptive treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!